These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30877503)

  • 21. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.
    Okabe S; Tauchi T; Tanaka Y; Kitahara T; Kimura S; Maekawa T; Ohyashiki K
    Cancer Biol Ther; 2014 Feb; 15(2):207-15. PubMed ID: 24100660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.
    Gleixner KV; Schneeweiss M; Eisenwort G; Berger D; Herrmann H; Blatt K; Greiner G; Byrgazov K; Hoermann G; Konopleva M; Waliul I; Cumaraswamy AA; Gunning PT; Maeda H; Moriggl R; Deininger M; Lion T; Andreeff M; Valent P
    Haematologica; 2017 Sep; 102(9):1519-1529. PubMed ID: 28596283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
    Zhou H; Mak PY; Mu H; Mak DH; Zeng Z; Cortes J; Liu Q; Andreeff M; Carter BZ
    Leukemia; 2017 Oct; 31(10):2065-2074. PubMed ID: 28321124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.
    Eiring AM; Page BDG; Kraft IL; Mason CC; Vellore NA; Resetca D; Zabriskie MS; Zhang TY; Khorashad JS; Engar AJ; Reynolds KR; Anderson DJ; Senina A; Pomicter AD; Arpin CC; Ahmad S; Heaton WL; Tantravahi SK; Todic A; Moriggl R; Wilson DJ; Baron R; O'Hare T; Gunning PT; Deininger MW
    Leukemia; 2015 Mar; 29(3):586-597. PubMed ID: 25134459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Asciminib: a new therapeutic option in chronic-phase CML with treatment failure.
    Yeung DT; Shanmuganathan N; Hughes TP
    Blood; 2022 Jun; 139(24):3474-3479. PubMed ID: 35468180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.
    Quentmeier H; Eberth S; Romani J; Zaborski M; Drexler HG
    J Hematol Oncol; 2011 Feb; 4():6. PubMed ID: 21299849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel therapeutic approaches in chronic myeloid leukemia.
    Özgür Yurttaş N; Eşkazan AE
    Leuk Res; 2020 Apr; 91():106337. PubMed ID: 32200189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Asciminib as a new option in the treatment of chronic myeloid leukemia.
    İbiş B; Tiribelli M; Eşkazan AE
    Future Oncol; 2021 Dec; 17(36):5003-5005. PubMed ID: 34791894
    [No Abstract]   [Full Text] [Related]  

  • 29. Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A.
    Salas A; Ponnusamy S; Senkal CE; Meyers-Needham M; Selvam SP; Saddoughi SA; Apohan E; Sentelle RD; Smith C; Gault CR; Obeid LM; El-Shewy HM; Oaks J; Santhanam R; Marcucci G; Baran Y; Mahajan S; Fernandes D; Stuart R; Perrotti D; Ogretmen B
    Blood; 2011 Jun; 117(22):5941-52. PubMed ID: 21527515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.
    Borgo C; Cesaro L; Salizzato V; Ruzzene M; Massimino ML; Pinna LA; Donella-Deana A
    Mol Oncol; 2013 Dec; 7(6):1103-15. PubMed ID: 24012109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.
    Zabriskie MS; Eide CA; Tantravahi SK; Vellore NA; Estrada J; Nicolini FE; Khoury HJ; Larson RA; Konopleva M; Cortes JE; Kantarjian H; Jabbour EJ; Kornblau SM; Lipton JH; Rea D; Stenke L; Barbany G; Lange T; Hernández-Boluda JC; Ossenkoppele GJ; Press RD; Chuah C; Goldberg SL; Wetzler M; Mahon FX; Etienne G; Baccarani M; Soverini S; Rosti G; Rousselot P; Friedman R; Deininger M; Reynolds KR; Heaton WL; Eiring AM; Pomicter AD; Khorashad JS; Kelley TW; Baron R; Druker BJ; Deininger MW; O'Hare T
    Cancer Cell; 2014 Sep; 26(3):428-442. PubMed ID: 25132497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1
    Gleixner KV; Sadovnik I; Schneeweiss M; Eisenwort G; Byrgazov K; Stefanzl G; Berger D; Herrmann H; Hadzijusufovic E; Lion T; Valent P
    Leuk Res; 2019 Mar; 78():36-44. PubMed ID: 30711891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ultra-deep sequencing mutation analysis of the BCR/ABL1 kinase domain in newly diagnosed chronic myeloid leukemia patients.
    Park H; Kim I; Kim HJ; Shin DY; Lee SY; Kwon OH; Kim DY; Lee KH; Ahn JS; Park J; Sohn SK; Lee JO; Cheong JW; Kim KH; Kim HG; Kim H; Lee YJ; Nam SH; Do YR; Park SG; Park SK; Bae SH; Song HH; Oh D; Jung CW; Park S
    Leuk Res; 2021 Dec; 111():106728. PubMed ID: 34673444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy.
    Gibbons DL; Pricl S; Posocco P; Laurini E; Fermeglia M; Sun H; Talpaz M; Donato N; Quintás-Cardama A
    Proc Natl Acad Sci U S A; 2014 Mar; 111(9):3550-5. PubMed ID: 24550512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
    Moore FR; Yang F; Press RD
    Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of PI3K/mTOR overcomes nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2.
    Ding J; Romani J; Zaborski M; MacLeod RA; Nagel S; Drexler HG; Quentmeier H
    PLoS One; 2013; 8(12):e83510. PubMed ID: 24349524
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Asciminib: First Approval.
    Deeks ED
    Drugs; 2022 Feb; 82(2):219-226. PubMed ID: 35041175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive models for designing potent tyrosine kinase inhibitors in chronic myeloid leukemia for understanding its molecular mechanism of resistance by molecular docking and dynamics simulations.
    Melge AR; Kumar LG; K P; Nair SV; K M; C GM
    J Biomol Struct Dyn; 2019 Nov; 37(18):4747-4766. PubMed ID: 30580670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigating Potential Cardiovascular Toxicity of Two Anti-Leukemia Drugs of Asciminib and Ponatinib in Zebrafish Embryos.
    Lin HC; Saputra F; Audira G; Lai YH; Roldan MJM; Alos HC; Aventurado CA; Vasquez RD; Tsai GJ; Lim KH; Hsiao CD
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.